Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 3/20 | 0.53 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.53 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.53 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.53 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.53 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3076603 | 0.89 | PSEN1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL21326091 | 0.89 | PSEN1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5769009 | 0.87 | PSEN1 (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1660384 | 0.85 | ELANE (0.49) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL757314 | 0.84 | NR1H2 (0.45) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8658861 | 0.83 | HTR2C (0.53) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL757756 | 0.83 | HTR2C (0.53) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3159251 | 0.82 | P2RX7 (0.49) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL20449200 | 0.82 | P2RX7 (0.49) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13634009 | 0.80 | PSEN1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049517-B1 | AMINO-PIPERIDINE DERIVATIVES AS CETP INHIBITORS | NOVARTIS AG (CH) | 2013-11-27 | — | — | EP | disclosed |
| US-20090286790-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-11-19 | — | — | US | disclosed |
| US-20090286790-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-11-19 | — | — | US | disclosed |
| US-20090286790-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-11-19 | — | — | US | disclosed |
| EP-2049517-A1 | AMINO-PIPERIDINE DERIVATIVES AS CETP INHIBITORS | Novartis AG (CH) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008009435-A1 | AMINO-PIPERIDINE DERIVATIVES AS CETP INHIBITORS | NOVARTIS AG (CH) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008009435-A1 | AMINO-PIPERIDINE DERIVATIVES AS CETP INHIBITORS | NOVARTIS AG (CH) | 2008-01-24 | — | — | WO | disclosed |
| CN-1042335-C | 1-acylpiperidine compounds | NORVATIS AG (CH) | 1999-03-03 | — | — | CN | disclosed |
| US-5646144-A | FOR TREATING DISORDERS IN WHICH SUBSTANCE P PLAYS A PART IN DEVELOPMENT | CIBA-GEIGY CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| US-5541195-A | SUBSTANCE P ANTAGONISTS | CIBA-GEIGY CORPORATION (US) | 1996-07-30 | — | — | US | disclosed |
| EP-0532456-B1 | 1-Acylpiperidine derivatives and their use as substance P antagonists | CIBA GEIGY AG (CH) | 1995-03-29 | — | — | EP | disclosed |
| US-5310743-A | Substance P antagonist | CIBA-GEIGY CORP. (US) | 1994-05-10 | — | — | US | disclosed |
| EP-0532456-A1 | 1-Acylpiperidine derivatives and their use as substance P antagonists | CIBA-GEIGY AG (CH) | 1993-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286790-A1 | ORGANIC COMPOUNDS | CETP, NPC1, CES1 | PSEN1 461/4885PSEN2 966/4885APH1B 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.